Severe preeclampsia: anesthetic implications of the disease and its management.
Preeclampsia is a significant, multifactorial, multiorgan disease affecting 6%-8% of all pregnancies in the United States and is the third leading cause of maternal mortality. As such, it is incumbent upon any anesthesia provider involved in obstetric cases to be familiar with the varied manifestations of the disease, management goals from an obstetric standpoint, and the implications for provision of anesthesia in this patient group. Despite improvements in the diagnosis and management of preeclampsia, severe complications can occur in both the mother and the fetus. A systematic approach to the anesthetic evaluation is therefore necessary to reduce morbidity and mortality and to improve outcomes. The potential pitfalls of general anesthesia, including failed intubation, in these complicated patients make regional anesthesia the preferred choice in many cases. Recent studies have shown that spinal anesthesia is often appropriate for preeclamptic patients, even in severe cases. Nevertheless, it is important to be aware of the potential contraindications to neuraxial anesthesia and to prepare for the possibility of encountering a difficult airway.
Turner
Judi A
JA
Department of Anesthesiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1778, USA. jaturner@mednet.ucla.edu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000773:Anesthesia, Obstetrical; D000775:Anesthesia, Spinal; D000927:Anticonvulsants / Q000627:therapeutic use; D036861:Delivery, Obstetric; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D011247:Pregnancy; D012307:Risk Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000927:Anticonvulsants; D014665:Vasodilator Agents; D008278:Magnesium Sulfate